-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $42

Benzinga·08/13/2026 13:02:31
Listen to the news
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $39 to $42.